Header Logo

Connection

Allison Naleway to Papillomavirus Vaccines

Back to Details
This is a "connection" page, showing publications Allison Naleway has written about Papillomavirus Vaccines.
Allison Naleway
Connection Strength
4.269
Papillomavirus Vaccines
  1. Epidemiology of Upper Limb Complex Regional Pain Syndrome in a Retrospective Cohort of Persons Aged 9-30 Years, 2002-2017. Perm J. 2023 06 15; 27(2):75-86.
    View in: PubMed
    Score: 0.779
  2. Temporal Trends in the Incidence of Anogenital Warts: Impact of Human Papillomavirus Vaccination. Sex Transm Dis. 2020 03; 47(3):179-186.
    View in: PubMed
    Score: 0.625
  3. Implementing a Multipartner HPV Vaccination Assessment and Feedback Intervention in an Integrated Health System. J Public Health Manag Pract. 2017 Nov/Dec; 23(6):589-592.
    View in: PubMed
    Score: 0.532
  4. Evaluation of a surveillance case definition for anogenital warts, Kaiser Permanente northwest. Sex Transm Dis. 2014 Aug; 41(8):496-500.
    View in: PubMed
    Score: 0.425
  5. Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the vaccine safety Datalink, July 2006-June 2011. J Adolesc Health. 2013 Nov; 53(5):637-41.
    View in: PubMed
    Score: 0.403
  6. Extended surveillance to assess safety of 9-valent human papillomavirus vaccine. Hum Vaccin Immunother. 2022 12 30; 18(7):2159215.
    View in: PubMed
    Score: 0.190
  7. Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes. JAMA Netw Open. 2021 04 01; 4(4):e214340.
    View in: PubMed
    Score: 0.168
  8. Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses. J Infect Dis. 2020 03 02; 221(6):910-918.
    View in: PubMed
    Score: 0.156
  9. Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019 12; 144(6).
    View in: PubMed
    Score: 0.153
  10. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination. Vaccine. 2019 06 27; 37(29):3918-3924.
    View in: PubMed
    Score: 0.148
  11. User-Centered Design for Developing Interventions to Improve Clinician Recommendation of Human Papillomavirus Vaccination. Perm J. 2017; 21:16-191.
    View in: PubMed
    Score: 0.126
  12. Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013. J Infect Dis. 2015 Dec 15; 212(12):1970-5.
    View in: PubMed
    Score: 0.113
  13. Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact. Cancer Causes Control. 2013 Feb; 24(2):403-7.
    View in: PubMed
    Score: 0.095
  14. Factors predicting completion of the human papillomavirus vaccine series. J Adolesc Health. 2013 Apr; 52(4):427-32.
    View in: PubMed
    Score: 0.095
  15. Reported adverse events in young women following quadrivalent human papillomavirus vaccination. J Womens Health (Larchmt). 2012 Apr; 21(4):425-32.
    View in: PubMed
    Score: 0.089
  16. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011 Oct 26; 29(46):8279-84.
    View in: PubMed
    Score: 0.087
  17. Completion and timing of the three-dose human papillomavirus vaccine series among adolescents attending school-based health centers in Oregon. Prev Med. 2011 Jun; 52(6):456-8.
    View in: PubMed
    Score: 0.085

© 2024 Kaiser Permanente